SARM1 NADase Inhibition for Axonal Preservation

SARM1 NADase Inhibition for Axonal Preservation

Overview

This therapeutic strategy targets SARM1 (Sterile Alpha and TIR Motif Containing 1), the genetically validated master executioner of Wallerian degeneration and programmed axon destruction. SARM1's intrinsic NADase activity rapidly depletes axonal NAD+ following injury or stress, triggering irreversible axon fragmentation. Pharmacological inhibition of SARM1's NADase domain represents one of the most compelling neuroprotective strategies across multiple neurodegenerative diseases where axonal degeneration is an early, driving pathology — including ALS, Parkinson's disease, and peripheral neuropathies.[@osterloh2012][@gerdts2013]

Target

• Primary Target: SARM1 NADase catalytic domain (TIR domain)
• Target Type: Small-molecule allosteric inhibitor or NAD+ competitive inhibitor
• Expression: Exclusively neuronal; enriched in long-projection axons (motor neurons, nigrostriatal tract, peripheral sensory neurons)
• Localization: Axonal mitochondria-associated; activated by rising NMN:NAD+ ratio upon mitochondrial stress

Mechanistic Rationale

Axonal degeneration precedes and often drives neuronal cell body death in most neurodegenerative diseases. The discovery that SARM1 is the obligate executioner of programmed axon degeneration — and that its genetic deletion provides complete axon protection — has made it one of the most validated neuroprotective targets in neuroscience.[@osterloh2012]

The SARM1 activation cascade:

...

SARM1 NADase Inhibition for Axonal Preservation

Overview

This therapeutic strategy targets SARM1 (Sterile Alpha and TIR Motif Containing 1), the genetically validated master executioner of Wallerian degeneration and programmed axon destruction. SARM1's intrinsic NADase activity rapidly depletes axonal NAD+ following injury or stress, triggering irreversible axon fragmentation. Pharmacological inhibition of SARM1's NADase domain represents one of the most compelling neuroprotective strategies across multiple neurodegenerative diseases where axonal degeneration is an early, driving pathology — including ALS, Parkinson's disease, and peripheral neuropathies.[@osterloh2012][@gerdts2013]

Target

• Primary Target: SARM1 NADase catalytic domain (TIR domain)
• Target Type: Small-molecule allosteric inhibitor or NAD+ competitive inhibitor
• Expression: Exclusively neuronal; enriched in long-projection axons (motor neurons, nigrostriatal tract, peripheral sensory neurons)
• Localization: Axonal mitochondria-associated; activated by rising NMN:NAD+ ratio upon mitochondrial stress

Mechanistic Rationale

Axonal degeneration precedes and often drives neuronal cell body death in most neurodegenerative diseases. The discovery that SARM1 is the obligate executioner of programmed axon degeneration — and that its genetic deletion provides complete axon protection — has made it one of the most validated neuroprotective targets in neuroscience.[@osterloh2012]

The SARM1 activation cascade:

Trigger: Mitochondrial stress, NMNAT2 depletion, or mechanical injury raises the axonal NMN:NAD+ ratio[@figley2021]

Activation: Rising NMN binds allosteric activation site on SARM1's ARM domain, inducing conformational change

NAD+ cleavage: Activated SARM1 TIR domain cleaves NAD+ into nicotinamide and cyclic-ADPR (cADPR), rapidly depleting the axonal NAD+ pool

Calcium surge: NAD+ depletion opens TRPM2 channels via cADPR, causing catastrophic calcium influx[@loreto2015]

Axon fragmentation: ATP depletion and calpain activation lead to cytoskeletal collapse and irreversible axon destruction

Cross-links to relevant mechanisms:

• SARM1 and Programmed Axon Degeneration
• Wallerian Degeneration
• NAD+ Metabolism
• Mitochondrial Dysfunction
• Calcium Dysregulation
• Neuroinflammation

Rubric Score

| Dimension | Score | Rationale |
|

Cross-Links

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/mechanisms/dopaminergic-neuron-vulnerability)
• [Huntington's Disease](diseases/huntingtons) — Metabolic dysfunction

Related Mechanisms

• Wallerian Degeneration — SARM1-mediated axonal death
• NAD+ Metabolism — SARM1 consumes NAD+
• Axonal Transport — Axonal integrity mechanisms
• Mitochondrial Dysfunction — Energy metabolism impairment

Related Proteins

• [SARM1](/mechanisms/dopaminergic-neuron-vulnerability)
• [NMNAT2](/mechanisms/dopaminergic-neuron-vulnerability)
• [PARP1](/mechanisms/dopaminergic-neuron-vulnerability)
• [CD38](/mechanisms/dopaminergic-neuron-vulnerability)

Related Cell Types

• Neurons — Primary target for neuroprotection
• Dopaminergic Neurons — PD-relevant neurons
• Motor Neurons — ALS-relevant neurons

Related Treatments

• SARM1 Inhibitors — SARM1-targeted small molecules
• NAD+ Precursors — NMN, NR supplementation
• Neuroprotective Agents — General neuroprotection

See Also

• [Axonal Degeneration](/mechanisms/axonal-degeneration)
• [NAD+ Metabolism](/mechanisms/dopaminergic-neuron-vulnerability)

External Links

• [SARM1 NADase Research](https://pubmed.ncbi.nlm.nih.gov/33298457/) — SARM1 inhibition studies

-----------|-------|-----------|
| Novelty | 8/10 | SARM1 is a genetically validated target with no approved therapies; first-in-class NADase inhibitors in early development |
| Mechanistic Rationale | 9/10 | One of the most robustly validated targets: SARM1-knockout mice show complete axon protection across injury and disease models |
| Addresses Root Cause | 8/10 | Axonal degeneration is a primary, early pathology in ALS, PD, and peripheral neuropathies — not just a downstream effect |
| Delivery Feasibility | 7/10 | Small-molecule inhibitors achievable; target is in peripheral axons (easy access) and CNS axons (needs BBB penetration) |
| Safety Plausibility | 8/10 | SARM1-knockout mice are healthy with normal lifespan; target is neuron-specific with limited peripheral expression |
| Combinability | 8/10 | Orthogonal to all current therapies; combines with NAD+ precursors (NR/NMN), anti-inflammatory, and anti-aggregation approaches |
| Biomarker Availability | 7/10 | Neurofilament light chain (NfL) directly tracks axonal damage; could use cADPR or NAD+ metabolites as PD markers |
| De-risking Path | 8/10 | Multiple validated animal models (SOD1-ALS, MPTP-PD, vincristine neuropathy); crystal structure solved enabling rational drug design |
| Multi-disease Potential | 9/10 | Validated in ALS, PD, traumatic brain injury, chemotherapy-induced neuropathy, diabetic neuropathy, glaucoma — broadest potential across neurological diseases |
| Patient Impact | 8/10 | Axon preservation is the difference between functional neurons and irreversible disability; early intervention could prevent progression |
| Total | 80/100 | |

De-risking Path

Phase 1 — Structure-guided design: Leverage published SARM1 TIR domain crystal structures (PDB: 6O0R, 7NAK) for rational inhibitor design targeting the NADase active site[@horsefield2019]

Phase 2 — Hit optimization: Screen isoquinoline and pyridine scaffolds identified as SARM1 inhibitors; optimize for potency, selectivity, and BBB penetration[@hughes2021]

Phase 3 — Target engagement: Measure axonal NAD+ preservation and cADPR reduction in DRG explant axotomy assays and iPSC-derived motor neurons from SOD1/C9orf72 ALS patients

Phase 4 — In vivo efficacy: SOD1-G93A ALS mice (axon survival, motor function), MPTP PD mice (nigrostriatal axon preservation, rotarod), and vincristine peripheral neuropathy model

Phase 5 — Clinical: Peripheral neuropathy indication first (simpler, measurable, reversible), then CNS indications; NfL as primary pharmacodynamic biomarker

Disease Coverage

| Disease | Relevance | Rationale |
|---------|-----------|-----------|
| ALS | High | Motor axon degeneration is primary pathology; SARM1 deletion extends survival in SOD1 mice[@white2019] |
| Parkinson's Disease | High | Nigrostriatal axons degenerate before DA neuron death; SARM1 drives MPTP axonopathy[@loreto2021] |
| Chemotherapy-Induced Neuropathy | High | Vincristine and paclitaxel activate SARM1; KO fully protects[@geisler2016] |
| Traumatic Brain Injury | High | Diffuse axonal injury is the primary pathology; SARM1 deletion preserves axons after TBI |
| Diabetic Neuropathy | Medium | Metabolic stress activates SARM1 in sensory neurons |
| Glaucoma | Medium | Retinal ganglion cell axons degenerate in optic nerve; SARM1 KO protects |
| Alzheimer's Disease | Low-Medium | Axonal transport deficits documented but cell body pathology more prominent |

Combination Therapy Potential

• With NAD+ precursors: NR/NMN replenish NAD+ pool while SARM1 inhibition prevents its catastrophic depletion — a "supply + save" strategy
• With anti-sense oligonucleotides (SOD1/C9orf72): ASO addresses root genetic cause while SARM1 inhibition prevents ongoing axon loss during treatment
• With riluzole: Glutamate reduction (riluzole) + axon preservation (SARM1i) in ALS
• With alpha-lipoic acid: Mitochondrial antioxidant reduces the metabolic stress that triggers SARM1 activation

Related NeuroWiki Pages

• SARM1 Gene | SARM1 Protein
• SARM1 and Programmed Axon Degeneration
• [Wallerian Degeneration](/mechanisms/wallerian-degeneration)
• TBK1 Gene | TBK1 Protein
• NAD+ Precursors
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Neurofilament Light Chain](/biomarkers/neurofilament-light-chain)

Cross-Links

Related Diseases

• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Peripheral Neuropathy](/mechanisms/dopaminergic-neuron-vulnerability)
• [Charcot](/diseases/charcot-marie-tooth-disease)

Related Mechanisms

• Wallerian Degeneration
• Axonal Degeneration
• NAD+ Metabolism
• Energy Depletion

Related Proteins

• [SARM1](/genes/sarm1)
• [NMNAT2](/genes/nmnat2)
• [NAD+](/therapeutics/nad-precursor-therapy)
• [PARP](/genes/parp4)

Related Cell Types

• Neurons
• Axons
• Schwann Cells

Related Treatments

• SARM1 inhibitors
• NMN analogs

Implementation Roadmap with Cost Estimates

Phase 1: Lead Identification and Preclinical Development (12-18 months)

Budget: $4-6M

| Milestone | Timeline | Activities | Lead |
|-----------|----------|-----------|------|
| Structure-based design | Months 1-6 | Crystal structure-guided inhibitor design targeting TIR domain NADase active site (PDB: 6O0R, 7NAK) | Computational chemistry |
| Hit identification | Months 3-8 | Screen isoquinoline/pyridine scaffolds; test 500+ compounds in SARM1 NADase assay | Contract screening |
| Lead optimization | Months 6-12 | Optimize for potency (IC50 < 100nM), BBB penetration (CLogP < 3), metabolic stability | Medicinal chemistry |
| Target engagement | Months 8-14 | DRG explant axotomy assay: NAD+ preservation, cADPR reduction | Academic collaborator |
| In vivo PK/PD | Months 10-16 | Mouse PK, brain exposure, axonal NAD+ levels | CRO partner |
| GLP toxicology initiation | Months 12-18 | 28-day rat toxicology for lead compound | GLP CRO |

Phase 2: Early Clinical Development (18-30 months)

Budget: $12-18M

| Milestone | Timeline | Activities | Lead |
|-----------|----------|-----------|------|
| Phase 1a (healthy volunteers) | Months 16-22 | SAD/MAD, safety, PK/PD | Clinical site |
| Phase 1b (CIPN patients) | Months 20-26 | Chemotherapy-induced peripheral neuropathy cohort; nerve function endpoints | Academic center |
| Phase 2a dose-finding | Months 24-32 | Biomarker readouts (NfL, cADPR), dose selection | Multi-site |

Phase 3: Efficacy and Registration (30-48 months)

Budget: $40-60M

| Milestone | Timeline | Activities | Lead |
|-----------|----------|-----------|------|
| Phase 2b efficacy (CIPN) | Months 30-40 | Registrational neuropathy trial; nerve conduction, patient-reported outcomes | Global CRO |
| Phase 2 (ALS) | Months 36-44 | Biomarker-guided trial in SOD1/C9orf72 ALS; NfL as primary endpoint | Academic centers |
| NDA/MAA submission | Months 44-54 | Peripheral neuropathy indication first; CNS indications via line extension | Regulatory affairs |

Total Estimated Cost: $56-84M

Key Academic Centers

• University of Michigan — Dr. Aaron DiAntonio (SARM1 biology, axon degeneration expertise)
• Washington University St. Louis — Dr. Jeffrey Milbrandt (NAD+ metabolism, NMN biology)
• University of Cambridge — Dr. Michael Coleman (Wallerian degeneration, SARM1 pharmacology)
• Stanford University — Dr. Lu Butler (SARM1 structural biology, cryo-EM)
• University of Pennsylvania — Dr. John Trojanowski (ALS biomarkers, clinical trials)

Potential Partner Companies

• Acquisition Labs — SARM1 inhibitor program (existing preclinical assets)
• Neurocrine Biosciences — CNS pipeline, neurology clinical infrastructure
• Biogen — ALS clinical trial expertise, biomarkers
• Eli Lilly — Pain/Neuropathy portfolio, clinical development capabilities
• Regeneron — Antibody and small molecule capabilities, CNS interest
• AbbVie — Pain and neurodegenerative disease portfolio

Risk Assessment

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Limited BBB penetration | Medium | High | Explore prodrug approaches; prioritize peripheral neuropathy indication first |
| Insufficient efficacy in CNS diseases | Medium | High | Use NfL as pharmacodynamic biomarker; enrich for rapidly progressing patients |
| Competition from gene therapy | Low | Medium | Small molecule has advantage of repeat dosing, reversibility |
| Peripheral target engagement | Low | Low | CIPN provides accessible peripheral readout; validates mechanism |
| Off-target NAD+ effects | Low | High | Structure-activity relationship optimization; selective for SARM1 TIR domain |

Actionable Next Steps

Lab Experiments

Allele-specific SARM1 inhibitor screening: Screen FDA-approved kinase inhibitors and natural product libraries for SARM1 NADase inhibition using in vitro NAD+ cleavage assays with purified SARM1 TIR domain. Prioritize compounds with established safety profiles for rapid repurposing potential.

Axon protection assays in patient-derived neurons: Test lead candidates in iPSC-derived motor neurons from SOD1 and C9orf72 ALS patients, as well as dopaminergic neurons from LRRK2 PD patients. Measure axonal NAD+ levels, cADPR production, and survival following mitochondrial stress (rotenone, CCCP).

In vivo target engagement validation: Establish pharmacodynamic biomarker assay measuring axonal NAD+ in peripheral nerve biopsies from treated mice. Correlate with behavioral recovery in SOD1-G93A and MPTP-PD models.

Combination synergy testing: Test SARM1 inhibitors in combination with NAD+ precursors (NR, NMN) and anti-inflammatory agents (minocycline, GLP-1 analogs) to identify synergistic neuroprotection in vivo.

Clinical Protocol Design

Chemotherapy-induced peripheral neuropathy (CIPN) first indication: Design Phase 1b trial in patients receiving vincristine or paclitaxel. Enrich for patients with demonstrated SARM1 activation (elevated plasma NMN:NAD+ ratio). Primary endpoint: nerve conduction velocity preservation at 3 months.

ALS enrichment strategy: Identify ALS patients with evidence of active axonal degeneration (rising NfL trajectory) for Phase 2. Use NfL as stratification biomarker to enrich for patients most likely to benefit from axon-preserving therapy.

Dose-finding with biomarker integration: Implement adaptive design with interim NfL analysis. Establish target NfL reduction threshold that predicts clinical benefit. Use cADPR in peripheral blood mononuclear cells as pharmacodynamic marker.

Combination protocol with NAD+ precursors: Design add-on study with concurrent NR or NMN administration. Test hypothesis that "replenish + protect" combination achieves superior axon preservation compared to either approach alone.

Company Partnership Opportunities

Acquisition Labs: Their existing SARM1 inhibitor program provides de-risked starting points. Propose co-development with milestone payments tied to IND clearance.

Ionis Pharmaceuticals: Explore ASO partnership for allele-specific SARM1 silencing in C9orf72 ALS. Combination of ASO-mediated gene reduction + small molecule axon protection addresses both cause and consequence.

Biogen: Leverage their ALS clinical trial infrastructure and biomarker capabilities. Propose biomarker-guided enrichment strategy using their existing NfL assay platform.

Vertex Pharmaceuticals: Their ion channel expertise and pain pipeline make them ideal partner for CIPN indication. Explore parallel development in diabetic neuropathy.

Procter & Gamble Consumer: For over-the-counter NAD+ precursor combinations (NR-based supplements), pursue co-formulation partnership for combination "neuroprotection" product.

References

[Osterloh JM, Yang J, Rooney TM, et al, dSarm/Sarm1 is required for activation of an injury-induced axon death pathway (2012)](https://pubmed.ncbi.nlm.nih.gov/22837781/)

[Gerdts J, Summers DW, Sasaki Y, DiAntonio A, Bhatt MP, Sarm1-mediated axon degeneration requires both SAM and TIR interactions (2013)](https://pubmed.ncbi.nlm.nih.gov/23516288/)

[Figley MD, Gu W, Bhatt MP, et al, SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33657413/)

[Loreto A, Di Stefano M, Gering M, Conforti L, Wallerian degeneration is executed by an NMN-SARM1-dependent late Ca2+ influx but only modestly influenced by mitochondria (2015)](https://pubmed.ncbi.nlm.nih.gov/26004910/)

[Horsefield S, Burdett H, Zhang X, et al, NAD+ cleavage activity by animal and plant TIR domains in cell death pathways (2019)](https://pubmed.ncbi.nlm.nih.gov/30728538/)

[Hughes RO, Bosanac T, Mao X, et al, Small molecule SARM1 inhibitors recapitulate the SARM1-/- phenotype and allow recovery of a metastable pool of axons fated to degenerate (2021)](https://pubmed.ncbi.nlm.nih.gov/33568399/)

[White MA, Lin Z, Kim E, et al, Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss (2019)](https://pubmed.ncbi.nlm.nih.gov/31474793/)

[Loreto A, Angeletti C, Gilley J, et al, Neurotoxin-mediated axon damage precedes and is slower in SARM1 null mice (2021)](https://pubmed.ncbi.nlm.nih.gov/33688638/)

[Geisler S, Doan RA, Strickland A, Bhatt MP, et al, Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice (2016)](https://pubmed.ncbi.nlm.nih.gov/27158753/)

[Gilley J, Orsomando G, Nascimento-Ferreira I, Coleman MP, Absence of SARM1 rescues development and survival of NMNAT2-deficient axons (2015)](https://pubmed.ncbi.nlm.nih.gov/25713132/)

[Summers DW, DiAntonio A, Bhatt D, Bhatt MP, DLK mediates the action of SARM1 but is dispensable for NMNAT2 loss-of-function in a murine model of disease (2020)](https://pubmed.ncbi.nlm.nih.gov/31862803/)

[Characterization of Novel SARM1 Inhibitors for the Treatment of Chemotherapy-Induced Peripheral Neuropathy (2024), Novel SARM1 Inhibitors for CIPN (2024)](https://pubmed.ncbi.nlm.nih.gov/39335636/)

[Pyridine-based small molecule inhibitors of SARM1 alleviate cell death caused by NADase activity (2024), Pyridine-based SARM1 inhibitors (2024)](https://pubmed.ncbi.nlm.nih.gov/39072360/)

[Inhibiting the SARM1-NAD(+) axis reduces oxidative stress-induced damage to retinal and nerve cells (2024), SARM1-NAD axis inhibition (2024)](https://pubmed.ncbi.nlm.nih.gov/38723372/)

[The Role of NMNAT2/SARM1 in Neuropathy Development (2024), NMNAT2/SARM1 in neuropathy (2024)](https://pubmed.ncbi.nlm.nih.gov/38275737/)

[Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives (2024), CMT2A therapeutic perspectives (2024)](https://pubmed.ncbi.nlm.nih.gov/38452947/)

Pathway Diagram

The following diagram shows the key molecular relationships involving SARM1 NADase Inhibition for Axonal Preservation discovered through SciDEX knowledge graph analysis: